Objective:To explore the characteristics of original site of premature ventricular contraction (PVC) in pa‐tiets with acute myocardial infarction (AMI) .Methods:Among ECG‐detected single‐source PVC patients ,a total of 150 idiopathic PVC patients and 150 AMI patients were randomly selected as control group and AMI group respec‐tively .Original sites of PVC was compared between AMI group and control group and between left and right ventri‐cle of AMI group ,and the relationship between original sites of PVC and diseased coronary in AMI patients was an‐alyzed .Results:Compared with control group ,there was significant rise in percentage of PVC originated from left ventricular apex (6.0% vs .46.0% ) ,and significant reductions in percentages of PVC originated from right ventric‐ular outflow tract (54.7% vs .27.3% ) and right ventricular anterior wall (10.0% vs .3.3% ) in AMI group , P<0.05 or <0.01. In AMI group ,compared with PVC originated from right ventricular outflow tract ,there was sig‐nificant rise in incidence rate of PVC originated from left ventricular apex (27.3% vs .46.0% ) , P=0.001 ;com‐pared with right ventricle , there was significant reduction in incidence rate of outflow tract PVC (66.1% vs . 13.6% ) ,and significant rise in incidence rate of apex PVC (24.4% vs .78.4% ) in left ventricle , P<0.01 both . Relevance test analysis of two‐way disordered classified data indicated that diseased coronary was not related to orig‐inal sites of PVC in AMI patients (χ2 =0.519 ,P=0.134) .Conclusion:Original sites of premature ventricular con‐traction has its own characteristics in patients with acute myocardial infarction ,which may possess certain guidance significance for its treatment .

Objective To investigate the clinical status about the utility of compound amino acid (15) and dipeptides (2) in-jection, and to promote the rational drug use in our hospital .Methods Data from 127 patients who used compound amino acid (15) and dipeptides(2) injection in surgical wards were collected in July 2012.The data about the drug usage method , duration, administra-ted timing, drug combination and the differences in all departments was analyzed .Results Existing problems:62.2% patients used compound amino acid (15) and dipeptides (2) injection by peripheral intravenous infusion , 6.3% patients used more than 14 days and 7.1%patients infused singly.Conclusion Compound amino acid(15) and dipeptides(2) injection had problems of off-label drug use in surgical ward , which need to be improved .

Objective:To retrospectively analyze the treatment status of tyrosine kinase inhibitors (TKI) in newly diagnosed patients with chronic myeloid leukemia (CML) in China.Methods:Data of chronic phase (CP) and accelerated phase (AP) CML patients diagnosed from January 2006 to December 2022 from 77 centers, ≥18 years old, and receiving initial imatinib, nilotinib, dasatinib or flumatinib-therapy within 6 months after diagnosis in China with complete data were retrospectively interrogated. The choice of initial TKI, current TKI medications, treatment switch and reasons, treatment responses and outcomes as well as the variables associated with them were analyzed.Results:6 893 patients in CP ( n=6 453, 93.6%) or AP ( n=440, 6.4%) receiving initial imatinib ( n=4 906, 71.2%), nilotinib ( n=1 157, 16.8%), dasatinib ( n=298, 4.3%) or flumatinib ( n=532, 7.2%) -therapy. With the median follow-up of 43 ( IQR 22-75) months, 1 581 (22.9%) patients switched TKI due to resistance ( n=1 055, 15.3%), intolerance ( n=248, 3.6%), pursuit of better efficacy ( n=168, 2.4%), economic or other reasons ( n=110, 1.6%). The frequency of switching TKI in AP patients was significantly-higher than that in CP patients (44.1% vs 21.5%, P<0.001), and more AP patients switched TKI due to resistance than CP patients (75.3% vs 66.1%, P=0.011). Multi-variable analyses showed that male, lower HGB concentration and ELTS intermediate/high-risk cohort were associated with lower cytogenetic and molecular responses rate and poor outcomes in CP patients; higher WBC count and initial the second-generation TKI treatment, the higher response rates; Ph + ACA at diagnosis, poor PFS. However, Sokal intermediate/high-risk cohort was only significantly-associated with lower CCyR and MMR rates and the poor PFS. Lower HGB concentration and larger spleen size were significantly-associated with the lower cytogenetic and molecular response rates in AP patients; initial the second-generation TKI treatment, the higher treatment response rates; lower PLT count, higher blasts and Ph + ACA, poorer TFS; Ph + ACA, poorer OS. Conclusion:At present, the vast majority of newly-diagnosed CML-CP or AP patients could benefit from TKI treatment in the long term with the good treatment responses and survival outcomes.